# A Study to Demonstrate Safety and Efficacy of Advagraf in Patients Undergoing Kidney or Liver Transplantation in India

> **NCT02432053** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 92 (actual)

## Conditions studied

- Kidney Transplantation
- Liver Transplantation

## Interventions

- **DRUG:** Advagraf

## Key facts

- **NCT ID:** NCT02432053
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2015-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02432053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02432053, "A Study to Demonstrate Safety and Efficacy of Advagraf in Patients Undergoing Kidney or Liver Transplantation in India". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02432053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*